Home / Transcripts / BioCryst Pharmaceuticals, Inc. (BCRX) · November 4, 2026

BioCryst Pharmaceuticals, Inc. (BCRX) Earnings Call Transcript

November 4, 2026

NASDAQ US Health Care Biotechnology earnings 42 min

Earnings Call Speaker Segments

Nick Wilder executive
#1

Good morning, everyone, and thank you for joining BioCryst's third-quarter 2026 corporate update and financial results conference call. With me today are Charlie Gayer, our President and CEO; Babar Ghias, our Chief Financial Officer; and Dr. Sandeep Menon, our Chief R&D Officer. You can find a press release and slide presentation covering today's news on our Investor Relations website. This call includes forward-looking statements — among them statements about future results, unaudited and forward-looking financial information, and the company's future performance and/or achievements. Such statements carry known and unknown risks and uncertainties that could cause our actual results, performance, or achievements to differ materially from any future results or performance expressed or implied in this presentation. For more information, including a detailed discussion of these risks, please see slide two of the presentation. Today's conference call also includes non-GAAP financial measures. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measure is provided in the earnings press release available on our Investor Relations website. I'd now like to hand the call over to Charlie.

Charlie Gayer executive
#2

Thank you, Nick. For BioCryst, the third quarter mattered a great deal, since we kept up robust execution while the company underwent strategic change. Where HAE is concerned, the number of new prescriptions written for Orladeyo held steady at the elevated mark we've maintained throughout the year. Once more, we brought on additional prescribers faster than the average pace seen over the last several years, and our overall treated-patient base expanded at a solid clip this quarter. Launching Orladeyo pellets for children in August was a moment we were excited about, and the initial performance indicators remain encouraging. Kids spanning every age from 2 through 11 have begun treatment with Orladeyo pellets, and the breakdown among those moving over from other prophylactic therapies, those coming from acute-only treatment, and those who had never received treatment has come out evenly balanced. That balance hints the pediatric market could exceed the 500 patients we've cited before; we're likewise eager to introduce the just-approved 150 mg Orladeyo pellets at this month's American College of Allergy, Asthma & Immunology meeting; this fresh formulation, for ages 12 and up, gives an option to children who began on pellets, to teens and adults who struggle to swallow a capsule, or to anyone who just likes the pellet form better. We anticipate producing real-world evidence that will let us follow progress and usage patterns among every patient on Orladeyo pellets. In Q3, we also completed the shift to CareMed as the single pharmacy partner handling shipments to patients. Our reason for moving to CareMed was that Orladeyo's patient volume has climbed so far that pharmacy-level operational excellence can now meaningfully affect both growth in treated patients and shipments of paid product; we're collaborating closely with CareMed to fold best practices into our EMPOWER Patient Services program, and the early signals from this partnership encourage us. We think CareMed can grow alongside us as our lineup of HAE prophylactic options keeps expanding. Shifting to the pipeline: as previously disclosed, the pivotal study of navenibart reached full enrollment in June, and we still expect to report top-line results covering 12 months of therapy during Q3 of next year. Our people are hard at work on the BLA submission and on launch preparations for the day we bring this potentially transformative product into our HAE portfolio. Staying on the strong-execution theme, we have now enrolled part four of the BCX17725 study in Netherton syndrome patients and remain on schedule to obtain early clinical data before this year ends. No therapies are approved for this devastating skin condition, which we estimate affects no fewer than 3,000 patients in the United States by itself. After the data readout, we'll examine the full dataset—covering key efficacy measures such as IASI, the Ichthyosis Area Severity score, plus safety and tolerability—to guide possible next steps for the program. Lastly, we're enthusiastic about the strategic pivot we're making to build our pipeline by way of external innovation. Not long ago we announced a scientific advisory board made up of top experts from the biotech industry, who will work alongside us to fulfill that strategy. These highly regarded advisors, who bring a successful track record, didn't come aboard merely for the prestige of serving on the board. They came aboard because they're convinced that BioCryst' profitability, discipline, and strong execution put the company in position to succeed with our rare disease strategy; and with that, I'll hand things over to Babar to walk through our increasingly strong financial position.

Babar Ghias executive
#3

Thanks, Charlie. We're pleased to share results for a very strong third quarter — one that included both the important milestones we just described and continued financial momentum. The intentional, forward-looking steps we've taken throughout this year, all designed to set BioCryst on a course toward durable growth and improving profitability, continue to be reflected in our financial performance. In my remarks today, I'll reference particular non-GAAP financial measures, which adjust for revenue and expenses related to our former European Orladeyo business, stock-based comp, costs from closing the Birmingham site and organizational restructuring, and expenses connected with the Astria acquisition. Additional detail on those adjustments appears in the press release issued today. In our view, these non-GAAP measures offer investors a useful picture of how the ongoing business is really performing. So let's begin with revenue. Orladeyo net revenue was $174.8 million for the quarter, with more than 95% of that coming from the US business; on a comparable basis, excluding European revenue, Orladeyo revenue climbed 20% year-over-year. Orladeyo revenues were helped this quarter by the CareMed transition. One advantage of shifting to a larger specialty pharmacy is that it holds inventory at multiple sites and provides a broader range of operating hours, which enables prompt fulfillment and efficient response to patient demand. Ordinarily, a pharmacy of this kind stocks enough product to cover about one to three weeks. As part of moving to this model, CareMed raised its inventory during the third quarter to roughly the low end of that range, which contributed revenue in the upper teens of millions of dollars for the quarter. Because we expect their inventory to stay at that lower end, revenue going forward should track underlying patient demand more closely. Any transition like this naturally brings some near-term operational complexity as systems and processes are put in place, but we're highly encouraged by the progress made so far. Although it's still early, we're already seeing fewer days to first shipment for new patients — an important measure of the patient experience. Even with the transition, and even after removing the impact of the inventory build, Orladeyo revenue excluding Europe still grew year-over-year. That demonstrates that favorable patient dynamics across the approved population remain in place. Throughout this process, our priority has stayed the same: maintaining a high-quality patient experience and uninterrupted access to Orladeyo. Before I turn to operating expenses, let me provide some context on this quarter's GAAP to non-GAAP adjustments. They mainly arise from closing our Birmingham facility and the associated organizational restructuring, which is still on track to be largely complete by year-end. Of the approximately $19 million in restructuring-related expenses recorded this quarter, only $10 million represent actual cash outlays. The remaining noncash portion largely came from accounting write-downs on assets that will hold no economic value once the closure is complete. The key thing to focus on is the structural upgrade we're delivering to our cost base. When these actions are fully realized, they should produce roughly $30 million to $35 million in annualized savings, and additional savings may surface as certain programs wind down. Looking ahead to 2027, the business as currently constituted is set up for continued revenue growth, with an operating cost base below the level we'll see in 2026. We'll provide formal 2027 guidance at the right time, but collectively, these pieces should support ongoing growth in profitability. Turning now to operating expenses: non-GAAP operating expenses were modestly under the prior year, in line with the financial discipline we've stressed. We're investing actively in the Phase 3 development program for navenibart, which is understandably a big driver of R&D spending. At the same time, we take a disciplined, data-driven approach to capital allocation across the rest of the pipeline. BCX17725 is a good example. Our approach has been to generate early clinical data in patients first, then let those data prospectively inform how much future investment is appropriate. We remain on track to make those data available before year-end. Sales and marketing costs were slightly above the prior-year figure, largely due to fees tied to the transition of our specialty pharmacy arrangement, and G&A spending has stayed essentially flat; this operating leverage from our trends is increasingly visible in our results. Non-GAAP operating profit was $86 million for the quarter, up 70% year-over-year, and non-GAAP net income of $71 million was more than double the prior-year period. With profitability still climbing, we also expect benefits from our substantial net operating loss carryforwards, which should limit cash taxes over the medium term, subject to applicable tax rules and limitations. That positions us for potentially strong expansion in both profits and cash flow. Our liquidity is solid, with cash and equivalents of $376 million. As noted earlier, we've deliberately moved toward external innovation, though we'll stay disciplined in how we build the pipeline. What matters most to us isn't stuffing the pipeline with more programs just to add size; it's identifying opportunities where BioCryst can deliver meaningful value to patients and shareholders. In the meantime, we'll keep evaluating ways to strengthen the balance sheet and return capital, all while maintaining the financial flexibility required to invest in compelling innovation. Now let's move to our 2026 financial guidance. Our Orladeyo revenue guidance was set without incorporating any benefit from the first specialty pharmacy inventory build. Because the CareMed transition is still at a relatively early stage of implementation, we aren't updating that guidance at this time. The progress we're seeing is encouraging, yet we recognize that launch experience, systems, and operating knowledge built up over six years are being transferred between partners on a compressed timeline. Importantly, we see this as a temporary transition rather than an ongoing operating condition. Patient demand and the underlying trends are still solid, and we're excited to broaden the pediatric launch while making the newly cleared oral pellet formulation available to HAE patients aged 12 and older, giving us an uninterrupted continuum of oral treatment options. On the other side, we're raising our total revenue guidance to $715 million to $730 million, reflecting higher licensing revenue actually recorded as well as international Rapivab orders placed by our partner. I want to stress that Rapivab isn't a strategic core asset for us — it operates largely as a pass-through business with thin margins. Turning to costs, we're once again narrowing our full-year operating expense guidance, now to $415 million to $425 million for 2026. As we capture the full 2026 benefit from those measures, we anticipate operating expenses will fall further in 2027, even while the core business keeps growing. In summary, the third quarter was exceptionally strong, and so were the first nine months of 2026. With one quarter to go, we're focused on a strong close to the year and entering 2027 from a position of considerable strength — revenue is climbing, our cost structure is becoming more efficient, profitability is increasing, liquidity is solid, and meaningful pipeline catalysts are ahead. We believe we have an opportunity to make 2027 a transformational year for BioCryst. Everyone across the organization is focused on delivering against that opportunity, and I'm very thankful to our colleagues throughout BioCryst for everything they've achieved this year. With that, operator, we're ready now to take questions.

Gavin Clark-Gartner analyst
#4

Hi, everyone. It's really good to see the progress, and I appreciate you taking my question. First, I just want to get some clarity on the inventory. The CareMed inventory build contributed in the upper teens. How do you expect that to trend in the next quarter? Should we expect a reversal of a similar amount? Is there still some amount of inventory build to come? What should we be thinking about for next quarter?

Babar Ghias executive
#5

Thanks for the question, Gavin. I believe your intuition is right. It's a one-time inventory build that they have to do for dispensing. As I mentioned on the call, our expectation is that typically they hold 7 to 31 days of 7 to 21 days of inventory. This quarter, we were at the lower side of that range, and we expect that to stay on the lower side. You shouldn't expect a one-time benefit, or I guess a recurring benefit, of inventory every quarter from this point onwards. In the nearer term, in another quarter, there may be small fluctuations, but as it gets smoothed out, it should reflect patient demand. To summarize, it really was a one-time benefit of this order of magnitude, and that should be the expectation.

Gavin Clark-Gartner analyst
#6

Great, that helps. Just one quick follow-up: what pediatric prescriptions did you see during this quarter?

Charlie Gayer executive
#7

Gavin, we won't be breaking out the specific figures, but it stayed strong. At the end of July — I believe it was the end of July — we announced 47, and that was well ahead of what we expected for the year. We remain ahead of our expectations. Pediatric revenue is still going to make up a very small portion of this year's revenue, but it's a good sign for the future. As I said, we're looking forward to beginning to gather real-world evidence in this population. I think as a bit more time passes, we'll have more to report out in the future.

Gavin Clark-Gartner analyst
#8

Great, thank you both.

Laura Chico analyst
#9

Morning. Appreciate you taking my question. I'd like to dig into something more strategic, if I could. Can you say more about what you laid out regarding the outlook for the HAE franchise in 2033 and past that point? If I'm reading the slides right, it seems you're framing it as roughly $1.4 billion to $2.0 billion by 2033. Previously, I believe you described this as an opportunity of $1.8-plus billion. Help me understand the dynamics feeding into the low end and the high end. What has to go right, and has anything shifted that would change your view? Thanks.

Charlie Gayer executive
#10

Thank you, Laura. That range we gave is in fact grounded in sell-side analyst estimates for the portfolio, and the reason we shared it is that, directionally, we're aligned on the two products that will have the most established oral presence by then — the market-leading oral prophy, and then what we believe will be a truly transformative product with every-three- and six-month dosing in navenibart. That combination really lets us reach both major segments of the market: those favoring oral prophy and those favoring injectable prophy. What has to go right for that outcome is clearly continued expansion of Orladeyo, which we anticipate, and all of our forward-looking research metrics indicate that will keep going. And then a robust launch, which we're getting ready for with navenibart. Our research with physicians and patients shows that dosing at three and six months, with high efficacy and convenient administration, is something that captures their interest and will prompt patients to switch. The crucial factor will be how many patients currently on other injectable prophies are interested in benefiting from this longer-interval dosing and make the switch. That is going to be the main driver of the pace of our revenue growth and, ultimately, of the peak we reach with navenibart.

Laura Chico analyst
#11

Thanks, Charlie.

Charlie Gayer executive
#12

Thanks.

Steve Seedhouse analyst
#13

Oh, great. Thanks for taking the question. This is somewhat tied to the long-term revenue projections, but more specifically to Orladeyo and how sticky that is—have you done any updated market research following the deucrictibant prophylaxis Phase 3 results? Do you have a sense of whether that came in above, below, or roughly in line with what you've been modeling for really the past several years? Thanks.

Charlie Gayer executive
#14

Thanks, Steve. We haven't run specific research since the data came out. What we did do, though, is our big annual exercise that happens the middle of every year, where we speak with 175 HAE treaters, 100 patients, and 50 payers, and run it through a large conjoint exercise and market simulation model. For deucrictibant, remember that we always include all of our current and future competition with their best-case profile. The profile we used for deucrictibant was actually a little better than what they proved out in the Phase 3. Comparable, but a little better, and it showed that, yes, that product will gain share, as you'd expect, but what it won't do is take away the base of Orladeyo patients. We continue to see Orladeyo growing even in the face of future competition in a couple years from deucrictibant.

Steve Seedhouse analyst
#15

Great, thanks.

Stacy Ku analyst
#16

Hi there. We really appreciate you answering our questions. We've got a few things we'd like cleared up. To start, could you speak to how confident you are in reaching the upper end of the Orladeyo guidance you gave for the year, particularly in light of what you shared about inventory — we found all those details very helpful? That's one more inventory-related question; and then, regarding the pediatric launch, would you say it's more a matter of consistent incremental gains, or are you noticing somewhat of a bolus-style pattern with the pediatric prescriptions? Looking ahead to next year and the consensus figures, I realize you won't want to comment on this, but does that number take into account what you're anticipating from the pediatric launch, or would you consider that additional upside? Then, a third point of clarification: in our conversations with clinicians, they often have their patients record highly detailed information about their attacks for the purposes of payer reimbursement and access. As you assess the oral competitive landscape over the coming couple of years, do you have a solid understanding of what proportion of patients are well controlled on Orladeyo, with truly competitive reductions in attack rates, as people attempt to gauge how sticky the drug is? Many thanks.

Charlie Gayer executive
#17

Great. Thank you, Stacy. Let me address the second question along with those other items, and afterward Babar can cover inventory. Regarding pediatrics, the first thing is that we're observing consistent, robust growth in additions. Naturally, there was an initial surge, largely tied to the supply delay we experienced — so things started with a bolus. Those patients have since moved onto therapy, and we continue to see solid demand exceeding our initial projections. It has only been a matter of months, so we'll need to watch how long this trend lasts, but the early indicators look quite encouraging. Looking ahead for Orladeyo and into our 2027 guidance, pediatric patients will certainly factor into the picture. Once we have more data—real-world evidence, as I mentioned, and other findings we consider valuable—we might discuss additional details about how the pediatric segment fits within the overall breakdown. Regarding patients doing well on Orladeyo, we've noted previously that about 60% of those who begin treatment reach the 12-month mark. So those patients are mostly the very well-controlled ones, and they're the ones reaching a median attack rate—we've published real-world evidence on this—of roughly one-third of an attack each month. Generally, patients report meaningful decreases in attack rates no matter their starting point, whether they came off other prophylaxis or had never been on prophylaxis before; we believe we're retaining the patients who are doing well. They're achieving efficacy that's competitive in the market. So next, Babar, would you like to talk about that?

Babar Ghias executive
#18

Thanks, Stacy, for that question. Let me give you a bit more perspective on the pharmacy side. Look, ultimately, how any product performs ought to reflect patient demand rather than inventory dynamics. As Charlie said in his remarks, a pharmacy's performance can genuinely have a meaningful impact on how a product progresses. When we made that switch, we were reaching a point in scaling the product where we needed to work with a larger partner capable of supporting the vision for Orladeyo and potentially navenibart once it gets approved. When we think about essentially maintaining the guidance, at the start of the year we had a different pharmacy partner and a different operating model, one that wasn't necessarily incorporating inventory dynamics. As I said, what we don't want to do is artificially change the guidance, because fundamentally it should be about patient demand.

Charlie Gayer executive
#19

We're still early on that front, and at this moment we haven't felt a need to revise the Orladeyo guidance merely due to a one-time inventory dynamic. As I mentioned, once we're beyond this quarter — as you can understand, we've only had six weeks fully with CareMed, since implementation began sometime in the August timeframe, roughly six to eight weeks — we don't even have a full quarter behind us yet. Once we move past that, it should genuinely mirror patient demand. That's the reason we were being somewhat cautious and conservative about adjusting guidance right now, purely because of an inventory dynamic.

Stacy Ku analyst
#20

That's really useful. Thanks, everyone.

Jeremiah Lorentz analyst
#21

Hello. Jeremiah here, covering for Tazeen. Appreciate you taking our question. I'd like to ask about the Netherton readout expected near the end of the year. I'm wondering what the benchmark is, or what data level you're looking for, before advancing that program. And depending on whether the study succeeds, how fast could you get to pivotal stages? Thank you.

Charlie Gayer executive
#22

Sandeep, do you want to handle that

Sandeep Menon executive
#23

I'll take that one. Thank you for asking. Netherton syndrome is a truly devastating skin condition, and it involves several other layers of disease manifestation, among them immunity and inflammation. We're preparing for our data readout in December. What we'll present is the primary endpoint and the key secondary endpoints, plus, of course, the safety and tolerability profile. What good looks like at this stage: these patients currently have no treatment options, and given how severe the disease is, any clinically meaningful improvement still beats what patients have today; we've spoken with patients and the relevant KOLs, and we'll also be in discussions with the FDA very soon to essentially establish a benchmark. From where we sit, provided we can achieve 20 to 25% on the primary IASI score, that should represent a pretty good clinically meaningful endpoint, based on all the research we've conducted internally in conversation with the KOLs, and obviously the regulatory discussions that are still pending as well. I think we'll leave it there for now, and once the data reads out, we'll share more.

Charlie Gayer executive
#24

Naturally, we’ll also be seeking a degree of consistency in the fact pattern there, so we’ll examine this in several ways. What do we expect will come next? Would we proceed directly?

Sandeep Menon executive
#25

Next, essentially, we're going to look at all of the data in its entirety, and at this point, what we want is to do what's best for both the program and the patients. We aren't going to hurry into anything pivotal immediately. Based on what the data shows, we'll speak with the regulators and take the data in, because this is going to be the first-in-class, the first therapy ever to come for Netherton; we want to be very clear about where we intend to take this; we will be swift when it comes to making decisions and we will move quickly. At the same time, we will be highly scientifically rigorous and thoughtful in the way we advance the clinical development.

Jeremiah Lorentz analyst
#26

That's really useful. Appreciate it, folks.

Maury Raycroft analyst
#27

Good morning, and thanks for taking my questions. I want to change direction a bit and perhaps ask just one about BD. So with this new scientific advisory board, could you expand on what its mandate is and what your current thinking is on BD — specifically the kinds of assets you're aiming to in-license?

Sandeep Menon executive
#28

Thanks for asking, Maury. As you can tell, our scientific advisory board brings a highly distinguished background and an extremely strong record of success, and that includes Dr. Tony Manning, who chairs the SAB. This is a working scientific advisory board, as Charlie said. It isn't a situation where people show up just to occupy some plush seat here; they're engaged with us no less than a few times each week. We're rolling up our sleeves and reviewing multiple assets, as we've said previously. These will be early clinical assets — Phase 1 and Phase 2 for the most part — and we'll favor very, very clear biology; we won't gamble on anything far-fetched when it comes to an inflection point, and we'll make sure this stays aligned with our core strengths, since we have a commercial fabric we intend to leverage; that's the game we're playing, and over the coming months, once we have more information, we'll be prepared to share it. The bottom line is that the SAB is extremely seasoned. They've been there, done that, and we're collaborating as a team to reach a point where our pipeline is rich and valuable for our stakeholders.

Charlie Gayer executive
#29

Maury, I’d also like to build on that point. Of course, we have assembled a very capable group in-house, covering both scientific assessment and business development. That internal group comes up with the concepts, and once something sparks our interest, the SAB assists us in thoroughly pressure-testing it. Do we actually want to pursue this? We consider it an excellent partnership. It’s still early, things are going very smoothly, and we believe this will strongly reinforce our strategy.

Maury Raycroft analyst
#30

Understood. That helps. Perhaps one brief follow-up regarding Netherton. As you’re considering the program’s next steps, the press release says expenses tied to the program were lower in the third quarter. Any particular reasons for that? Is it simply because the study has enrolled and things are at a status quo, or how should we think about it?

Babar Ghias executive
#31

I’d trace that back to the financial discipline we’ve been putting in place throughout the organization, Maury, and essentially adopting an evidence-based approach. Here’s an example: in the past, we may have been somewhat aggressive in believing we needed to run a CMC campaign before actually seeing results. What I was mainly stressing earlier is that we’re taking a highly evidence-based, rigorous scientific approach—asking whether we first have a product and whether we have the available data that lets us unlock the next development step. Across the organization, we’ve been establishing that discipline, and Netherton, as I said, was a perfect example where we didn’t believe we needed to spend dollars at risk on things before we can actually unlock the data. That was essentially the main reason you’re seeing a decline in expense. I think that will be a theme, right? That’s how we’ll proceed and develop on this innovation aspect we’re discussing—BD—while also being very committed to delivering strong profitability going forward.

Sandeep Menon executive
#32

Maury, building on what Babar laid out so well, I want to add that we'll still move quickly. It's not as though we're going to make everything so sequential that the program gets delayed — that isn't the situation at all. Essentially, we'll gather some early data and place the right bets, the ones that will bring us scientific and development success, yeah.

Maury Raycroft analyst
#33

Got it. Thanks for taking my questions.

Sandeep Menon executive
#34

Yeah.

Silvia Luo analyst
#35

Hi, Silvia here, covering for Jess Fye. Thanks for taking our question. I just want to confirm: under the earlier model, before CareMed, was any inventory sitting in another location that still has to be drawn down, and might that be part of the reason for the reluctance to revise the Orladeyo guidance? And then a follow-up — I understand the conservatism right after this specialty pharmacy transition — but if that high-teens inventory benefit wasn't included in the fundamental Orladeyo guidance you've given and are keeping, would investors be mistaken to anticipate full-year Orladeyo revenue coming in at $650 to $655 million, which is simply the midpoint of the fundamental guidance plus $15 to $20 million? Thanks.

Charlie Gayer executive
#36

Thanks, Silvia. Regarding inventory from the prior pharmacy, the billing model was different there. Each pack shipped was a flash sale, so essentially no inventory existed. With CareMed, it's a somewhat more traditional pharmacy model, in which they purchase some inventory. As Babar described, it sits at a relatively low level, about a week's worth of inventory. No, from a guidance standpoint, given everything we see at this point and the changes that, as we're saying, we still haven't fully worked through, we view $625 million to $645 million as still the right guidance for the year.

John Gionco analyst
#37

Hello, and good morning to all of you. John here, filling in for Serge today. We appreciate you taking our questions. I have just a couple regarding Orladeyo. First, I'm curious whether you can give an update on the paid Rx rate as we exited the third quarter, and whether your outlook for where that rate could land has shifted given the efficiencies that have come out of the CareMed partnership. Second, on the pediatric front, you mentioned that the launch is running ahead of expectations. I'm just curious how you see the overall opportunity now compared with the original 500 patient pool. Thank you.

Charlie Gayer executive
#38

Thank you, John. On the paid rate, let me remind you of what usually occurs during the second half of the year: our paid rate generally reaches its peak in the second quarter, after all the reauthorizations have been worked through earlier in the year. After that, during the second half, it begins to decline gradually, largely because the rate is influenced more by new patients starting, and new patients do not reach the 80%-plus paid rate that the overall population has quite as fast. That same pattern is showing up, right in line with what we expected. I believe we closed the quarter at roughly 82, 83% paid. Regarding your CareMed question, we do believe that, with their capabilities combined with our team's efforts, we have an opportunity to hit and possibly surpass our long-term target of reaching an 85% paid rate as a kind of steady state, and we think we are on track for that. I'd also point out that with pediatrics, we are seeing very strong early paid rates. Pediatrics, as you'd expect, is essentially a commercial plus Medicaid business, with a somewhat different dynamic than our overall population, but the early signals show we are getting these kids to paid at a high rate, and I expect that to keep going. As for the overall opportunity in peds, yes, we are cautiously optimistic that it may turn out to be larger than we initially anticipated; it certainly is proving to be so this year. I think we need at least a couple more quarters to see what the steady state of demand looks like. There are still physicians out there who are still learning about this indication and have not yet acted, and so I think there is probably considerably more opportunity than the 500 diagnosed and treated patients we have previously prescribed?.

Brian Abrahams analyst
#39

Hello. Good morning, and thank you for taking our question. I'm wondering whether you're noticing any changes in how Orladeyo is being used following the recent introduction of oral on-demand treatments or other long-acting injectable prophylactic therapies? And then, secondly, I'd be interested to hear what your market research suggests about how the potential opportunity might differ if navenibart were able to show every-six-month dosing rather than every-three-months. Thank you.

Charlie Gayer executive
#40

Thank you, Brian. As we've mentioned previously, at this stage it has been more than a year since the oral acute entered the market, and then also the two new prophylactics that arrived last summer; we truly aren't observing any effect from the oral acute. Some Orladeyo patients are using it. Definitely no negative trends are showing up, though I also wouldn't describe it as anything especially positive. It simply hasn't made much of a difference to our business. Regarding the oral—sorry, the other longer-acting injectables, what we're genuinely finding is that when Orladeyo isn't the right fit for a patient, rather than preferentially switching to Takhzyro, a greater share of those patients are going to either Andembry or Dawnzira, which is exactly what you'd anticipate. Then with navenibart, what we're observing again across all the research we've conducted, three months is truly a transforma—every-three-month dosing is genuinely transformative, and then being able to offer three months and six months as options makes the overall package even stronger. We anticipate having both doses in our label based certainly on the Phase 2 data we've seen, with both doses showing very durable attack reduction. As for having that option, we don't yet know which dosage form—which frequency—would see the most use. I think that's something we'll learn more about. Having both genuinely makes navenibart a very strong option for patients and physicians, and it's really, really intriguing to them.

Brian Abrahams analyst
#41

Thanks.

Charlie Gayer executive
#42

Thanks. As we've laid out here, it was another truly solid quarter for BioCryst. Over this past year we've gone through a transformation on several fronts—leadership, strategy, and the way we operate the business—and I'd also like to express my appreciation to everyone, all of our colleagues at BioCryst, who put in such hard work throughout this year of transition, and I believe we've positioned ourselves for a genuinely great 2027 and beyond. Thank you, all.

Operator operator
#43

We appreciate everyone joining the conference today; that brings the program to a close. You're free to disconnect at this time.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete BioCryst Pharmaceuticals, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to BioCryst Pharmaceuticals, Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.